Among the available systemic anti-cancer treatments for melanoma, immunotherapy with immune checkpoint inhibitors, such as anti-programmed cell death protein-1 (anti-PD1) or programmed cell death protein ligand-1 (PDL1), has demonstrated remarkable clinical benefits, increasing life expectancy in advanced disease patients [5,6,7,8]. This evidence concerns the gene PDCD1 and cancer.